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1. INTRODUCTION 
1.1 ANALYTICAL CHEMISTRY 
Analytical chemistry is a branch of chemistry that deals with the separation, 
identification and determination of components in a sample. It is the science of 
making quantitative measurements, which requires background knowledge of 
chemical and physical concepts. The use of instruments is an exciting and fascinating 
part of chemical analysis that interacts with all areas of chemistry and with many 
other areas of pure and applied science. Analytical instruments plays an important 
role in the production and evaluation of new products, protection of consumers and 
environment, it also provides the lower detection limits required to assured safe foods, 
water and air
1
. Traditionally, analytical chemistry can be classified into two types 
 Qualitative analysis 
 Quantitative analysis 
Qualitative analysis gives an indication of the identity of the chemical species in the 
sample and quantitative analysis determines the amount of one or more of these 
components
2
.  
Classification of analytical techniques
3, 4 
The analytical techniques can be classified on the basis of type of properties in the 
following way.  
i) Chemical methods of analysis   
ii) Electrical methods of analysis  
iii) Optical methods of analysis  
iv) Nuclear radiation methods of analysis  
v) Thermal methods of analysis  
vi) Separation methods  
These methods can further be classified into different techniques depending on the 
measurement of a characteristic property based on either the nature or the amount of 
the desired constituent of the sample. 
i) Chemical methods of analysis 
These methods are based on the primary role of a chemical reaction. In these methods, 
the direct measurement of mass is carried out by one of the two procedures, i.e. by 
weighing or by measuring volume. 
 Gravimetry 
 Volumetry 
ii) Electrical methods of analysis   
An electrical method of analysis also known as electroanalytical method can be 
defined as one, in which an electrochemical property of a solution is measured. A 
classification of electroanalytical methods can be made by measuring different 
electrical quantities, such as, potential, current, quantity of current, resistance and 
dielectric constant. These methods have different names on the basis of the 
measurement of these quantities and are stated below.  
 Potentiometry  
 Amperometry  
 Voltammetry  
 Calorimetry  
 Conductometry and High Frequency Methods 
iii) Optical methods of analysis 
These methods are now called as spectroscopic methods of analysis. In these methods 
the first instruments were developed for use of visible region and therefore called 
optical methods. 
The important spectroscopic methods are mentioned below.  
 Emission Spectroscopy  
 Absorption Spectroscopy  
 Ultraviolet and Visible Absorption Spectroscopy  
 Infrared Absorption Spectroscopy  
 Photofluorometry  
 Turbidimetry and Nephelometry  
 Raman Spectroscopy 
iv) Nuclear methods 
Some techniques which can provide analytical information based on nuclear 
properties. Each of these properties or combinations of them can be studied suitably 
by analytical chemistry. Nuclear method can be group into following.  
 Radiochemical Methods  
 Radiometric Methods  
 Isotopic Dilution Methods   
 Activation Analysis   
 Mossbauer Spectroscopy  
 Nuclear Magnetic Resonance Spectroscopy  
 Mass Spectrometry 
 
v) Thermal methods of analysis 
In thermal methods of analysis some property of the system is measured as a function 
of temperature. In some of these methods the temperature is used as an independent 
variable while in some others as a dependent variable say time. The recorded curves 
are helpful in interpreting the thermal behaviour of the sample.  Some commonly used 
methods are: 
 Thermogravimetric Analysis (TGA)  
 Derivative thermo-gravimetry (DTG)  
 Differential Thermal Analysis (DTA)  
 Differential Scanning Calorimetry (DSC)  
 Thermometric Enthalpy Titrations (TET) 
vi) Separation methods   
In separations, in general by appropriate reactions, the desired constituent is brought 
into one phase and interfering elements are brought into another and the phases being 
separated by physical processes. Some methods of separation are the following:  
A. Classical methods  
 Precipitation   
 Distillation   
 Sublimation   
 Formation of complexes  
B. Modern methods   
 Chromatography   
 Solvent extraction   
 Ion-Exchange   
 Electrophoresis   
1.3 Important considerations in analytical methods
5 
 The instrument most visible and exciting element of the analytical method, 
only one component of the total analysis 
 The analyst should determine the nature of the sample, the end use of the 
analytical results, the species to be analyzed.  
 Quantitative information may include elemental composition, oxidation state, 
functional groups, major components, minor components, complete identification in 
the given sample. 
 Quantitative data include accuracy and precision, range of expected analyte.  
 Methods such as controlling the atmosphere to which the sample is exposed, 
controlling the temperature of the sample, buffering the pH of sample solutions. 
CHROMATOGRAPHY
6 
Chromatography is relatively a new technique which was first invented by M. Tswett, 
a botanist in 1906 in Warsaw. Chromatography is a physical separation method in 
which the components of a mixture are separated by differences in their distribution 
between two phases, one of which is stationary (stationary phase) while the other 
(mobile phase) moves through it in a definite direction. The substances must interact 
with the stationary phase to be retained and separated by it. 
 
 
 
 
 
CLASSIFICATION OF CHROMATOGRAPHY 
 
 
1.2. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
7
 
High-performance liquid chromatography (HPLC) is a form of liquid chromatography 
used to separate compounds that are dissolved in solution. High performance liquid 
chromatography is basically a highly improved form of column chromatography. 
Instead of a solvent being allowed to drip through a column under gravity, it is forced 
through under high pressures of up to 400 atmospheres. The compounds are separated 
Chromatography  
Partition  Adsorption Ion-
exchange 
Gel 
filtration 
Affinity HPLC 
Paper 
chromatography 
Thin layer 
chromatography 
Gas-liquid chromatography 
Column chromatographay 
Ascending 
Descending 
Circular or Radial 
Ascending & Descending  
by injecting a plug of the sample mixture onto the column. The different components 
in the mixture pass through the column at different rates due to differences in their 
partitioning behavior between the mobile liquid phase and the stationary phase.  
 Most of the drugs in multicomponent dosage form can be analyzed by HPLC method 
because of the several advantages like rapidity, specificity, accuracy, precision, and 
ease of automation in these methods. HPLC Method eliminates tedious extraction and 
isolation procedures. 
Principle 
 The principle involved in HPLC is separation of compounds in a mixture more 
efficiently and also quickly than that of traditional column chromatography. The 
separation of compounds is due to their relative differences in travel through the 
column on application of pressure exerted through mobile phase or carrying liquid. 
The compounds of the mixture travel with different rates due to their relative affinities 
with the solvent and stationary phase. Compounds with higher affinity towards 
stationary phase of the column travels slowly and vice-versa. The above principle is 
similar to that of column chromatography but in HPLC, The separation is more 
effective due to greater surface area achieved due to very small particle size of 
stationary phase in comparison to that used in column chromatography. This decrease 
in particle size increases has disadvantage that it proportionately enhances the flow 
time and run time due to increased surface area. To minimize this obstacle the high 
pressure is applied to the flow of mobile phase through the column by use of pumps. 
All factor affecting separation on liquid column chromatography apply to this 
techniques also, e.g. Plate height, sample, distribution between the stationary phase 
and liquid phases various methods of development of the chromatograms (elution, 
gradient elution etc) can be used in this technique. 
Instrumentation        
The HPLC System consist of  
1. A solvent reservoir and mixing system 
2. A high pressure pump. 
3. A sample inlet pump. 
4. A column. 
5. A detector and recording unit. 
 
 
 
 
 
             
 
Fig: 1 – Schematic representation of High performance liquid chromatography 
Apparatus and materials 
1. The column. 
2. Column packing 
3. Column packing procedure. 
4. Chromatography solvent (Mobile Phase) 
5. Pumping systems. 
6. Detector systems. 
7. Practical procedures. 
 
 
Different modes of separations in HPLC 
Normal Phase Mode:  
In these the stationary phase is polar and the mobile phase is non-polar in nature. In 
these techniques, non-polar compounds travel faster and are eluted first. This is 
because of the lower affinity between the non-polar compounds and the stationary 
phase. 
Reversed Phase Mode: 
 The stationary phase is Non-polar Hydrophobic packing with Octyl or Octa decyl 
functional group bounded to silica gel and the mobile phase is polar solvent. An 
aqueous mobile phase allows the use of secondary solute chemical equilibrium to 
control retention and selectivity. The polar compounds gets eluted first in this mode 
and non-polar compounds are retained for longer times. As most of the 
pharmaceutical drugs are polar in nature, they are not retained for longer times and 
hence elute faster. The different columns used are Octa Decyl Silane (C18), octa silane 
(C8), tetra silane (C4) etc. 
Ion Exchange Chromatography 
 The stationary phase contains ionic groups like NR3
+
 or SO3
- 
which interact with the 
ionic groups of the sample molecules. This is suitable for the separation of charged 
molecules only. 
Affinity Chromatography: 
 In these techniques highly specific biochemical interactions are used for separation. 
The stationary phase contains specific group of molecules which can absorb the 
sample if certain steric and charge related conditions are satisfied. 
 
 
Size Exclusion Chromatography:  
It separates molecules accordingly to their molecular mass. Largest molecules are 
eluted first and the smallest molecules last 
Applications    
 High pressure liquid chromatography more sensitive detectors, if promises to 
become more and more important. HPLC offers the advantages of speed, resolution 
and sensitivity. The column may be reversed. It is especially useful for separating the 
high molecular weight compounds which have either a two pressure or undergo 
pyrolysis when subjected to the higher required temperatures of has chromatography. 
 The chromatography of separation of barbiturates by HPLC method. 
 The wide applicability speed and selectivity of HPLC have resulted in it 
becoming the most popular form of chromatography virtually all type of biological 
molecule have been purified. 
 RP-HPLC is particularly useful for the separation of the polar components 
such as drugs and their metabolites, peptides, vitamins, polyphenol, and steroids. 
 
 
 
 
 
 
 
 
 
 
ANALYTICAL METHOD DEVELOPMENT 
Methods are developed for new products, when no official methods are available. 
Alternate methods for existing products are developed to reduce the cost and time for 
better precision and ruggedness. Trial runs are conducted, method is optimized and 
validated
8
. 
Steps of method development
9
: 
Documentation starts at the very beginning of the development process, a system for 
full documentation of the development studies must be established. All data relating 
to the studies must be recorded in laboratory notebook or electronic database. 
Analyte standard characterization: 
All known information about the analyte and its structure is collected i.e., physical 
and chemical properties, toxicity, purity, hygroscopic nature, solubility and stability. 
The standard analyte (100% purity) is obtained. Necessary arrangement is made for 
the proper storage (refrigerator, desiccators and freezer). When multiple components 
are to be analyzed in the sample matrix, the number of components is noted, data is 
assembled and the availability of standards for each one is determined. Only those 
methods (MS, GC, HPLC etc.,) that are compatible with sample stability are 
considered.  
2. Method requirements: 
The goals or requirements of the analytical method that need to be developed are 
considered and the analytical figures of merit are defined. The required detection 
limits, selectivity, linearity, range, accuracy and precision are defined. 
 
3. Literature search and prior methodology: 
The literature for all type of information related to the analyte is surveyed. For 
physical and chemical properties, solubility and relevant analytical methods. Books, 
periodicals, chemical manufacturers and regulatory agency compendia such as 
USP/NF, AOAC and ASTM publications are convenient. 
4. Choosing a method: 
Using the information in the literatures and prints, methodology is adopted. The 
methods are modified wherever necessary. Sometimes it is necessary to acquire 
additional instrumentation to reproduce, modify, improve or validate existing methods 
for in-house analytes and samples.If there is no prior methods for the analyte in the 
literature, from analogy, the compounds that are similar in structure and chemical 
properties are investigated and are worked out. There is usually one compound for 
which analytical method already exist that is similar to the analyte of interest. 
5. Instrumental setup and initial studies: 
The required instrumentation is setup. Installation, operational and performance 
qualification of instrumentation using laboratory standard operating procedures 
(SOP’s) are verified. Always new consumables (e.g. solvents, filters and gases) are 
used, for example, method development is never started, on a HPLC column that has 
been used earlier. Analyte standard in a suitable injection/ introduction solution and in 
known concentrations and solvents are prepared. It is important to start with an 
authentic, known standard rather than with a complex sample matrix. If the sample is 
extremely close to the standard (e.g. bulk drug), then it is possible to work with the 
actual sample. Analysis is done using analytical conditions described in the existing 
literature. 
6. Optimization: 
During optimization one parameter is changed at a time, and set of conditions are 
isolated, rather than using a trial and error approach. Work has been done from an 
organized methodical plan, and every step is documented (in a lab notebook) in case 
of dead ends. 
7. Documentation of analytical figures of merit: 
The originally determined analytical figures of merit limit of quantitation (LOD), 
limit of detection(LOQ), linearity, time per analysis, cost, sample preparation etc., are 
documented. 
8. Evaluation of method development with actual samples: 
The sample solution should lead to unequivocal, absolute identification of the analyte 
peak of interest apart from all other matrix components. 
9. Determination of percent recovery of actual sample and demonstration of 
quantitative sample analysis: 
Percent recovery of spiked, authentic standard analyte into a sample matrix that is 
shown to contain no analyte is determined. Reproducibility of recovery (average +/- 
standard deviation) from sample to sample and whether recovery has been optimized 
has been shown. It is not necessary to obtain 100% recovery as long as the results are 
reproducible and known with a high degree of certainity. The validation of analytical 
method can be verified only by laboratory studies. Therefore documentation of the 
successful completion of such studies is a basic requirement for determining whether 
a method suitable for its intended application. 
ANALYTICAL METHOD VALIDATION 
Validation
10, 11 
Validation of an analytical method is the process by which it is established, by laboratory 
studies, that the performance characteristics of the method meet the requirements for the 
intended analytical applications. 
Reasons for validation 
There are two important reasons for validating assays in the pharmaceutical industries. The 
frst, and by for the most important, is that assay validations is an integral part of the quality 
control system. The second is that current good manufacturing practice regulation requires 
assay validation. 
Typical validation characteristics  
 Accuracy 
 Precision 
 Range 
 Specificity 
  Linearity 
 Detection Limit 
 Quantification Limit 
 Ruggedness 
 Robustness 
 
 
 
Accuracy 
 The accuracy of an analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or on an accepted 
reference value and the value found. 
Precision 
 It expresses as degree of agreement among individual test results when procedure/method 
is applied to a homogeneous sample – usually expressed as SD/RSD. It is a measure of 
degree of repeatability or reproducibility under normal conditions. A more comprehensive 
definition proposed by the ICH divides precision into three types 
1. Repeatability. 
2. Intermediate precision. 
3. Reproducibility. 
Range 
 The range of a method can be defined as the upper and lower concentrations for 
which the analytical method has adequate accuracy, precision and linearity. The range of 
concentrations examined will depend on the type of method and its use. 
Specificity 
Ability of the method to measure accurately and specifically the analyte of interest in 
presence of matrix and other components likely to be present in the sample matrix and 
impurities, degradation products and other related substances. For this, one may compare 
the test results of analysis of samples containing other ingredients/ impurities / degradation 
products / related substances/placebo ingredients with those obtained from analysis of 
sample without these, i.e., the method must allow distinct analytical measurement of 
analyte of interest and exclusion of all other relevant interferences.  
If the impurities/degradation products or potential contaminants are not available, one can 
apply a proposed method to the strained and stressed (heat, light, humidity) samples. 
Degree of agreement among results will explain specificity of the method. 
If the impurities/degradation products are not available, one may carryout additional purity 
tests by chromatography-HPLC/HPTLC. 
Linearity 
 The linearity of an analytical procedure is its ability to obtain test results, which are 
directly proportional to the concentration of analyte in the sample. Linearity can be 
assessed by performing single measurements at several analyte concentrations. A linearity 
correlation coefficient above 0.999 is acceptable for most methods, especially for major 
components in assay methods. The range of an analytical procedure is the interval between 
the upper and lower concentration of analyte in the sample. 
Detection limit 
The Detection Limit of an individual analytical procedure is the lowest amount of analyte 
in a sample which can be detected but not necessarily quantitated as an exact value. The 
detection limit (LOD) may be expressed as 
                         LOD          =      3.3σ 
                                                      S  
              Where, 
    = the standard deviation of the response. 
 S   = the slope of the calibration curve (of the analyte). 
Quantification limit 
LOQ is defined as the lowest concentration of the substance (analyte) in a sample that 
can be estimated quantitatively with acceptable precision, accuracy and reliability by 
a given method under stated experimental conditions. Quantification Limit (LOQ) 
may be expressed as 
      LOQ           =       10 
                                               S 
 
Where, 
   =          the standard deviation of the response. 
  S    = the slope of the calibration curve (of the analyte). 
Ruggedness 
 It is the measure of the capacity of the analytical method to remain unaffected 
by small but deliberate variations in procedure. It provides an indication about 
variability of the method during normal laboratory conditions. 
Robustness 
 The concept of robustness of an analytical procedure has been defined by the 
ICH as ―a measure of its capacity to remain unaffected by small, but deliberate 
variations in method parameters‖. The most important aspect of robustness is to 
develop methods that allow for expected variations in the separation parameters. 
System suitability 
           System suitability is the checking of a system to ensure system performance 
before or during the analysis of unknowns. Before performing any validation 
experiment, you should establish that the HPLC and the procedure are capable of 
providing data of acceptable quality. These tests are to verify that the resolution and 
repeatability of the system are adequate for the analysis to be performed. It is based 
on the concept that equipment, electronics, analytical operations and sample constitute 
an integral system that can be evaluated as a whole. 
 
 
 
 
System suitability parameters and recommendations 
S. No Parameters Recommendations 
1 Theoretical plates (N) >2000 
2 Tailing factor (T) ≤ 2 
3 Resolution (Rs) > 2 between peak of interest and the closest 
eluting potential interference 
4 Repeatability  RSD ≤ 1% for N ≥5 is desirable 
5 Capacity factor (k
1
) > 2.0 
6 Relative retention Not essential as long as the resolution is stated 
 
System suitability parameters
12 
System suitability testing is an integral part of many analytical procedures. The tests 
are based on the concept that the equipment, electronics, analytical operations, and 
samples to be analyzed constitute an integral system that can be evaluated as such. 
System suitability test parameters to be established for a particular procedure depend 
on the type of procedure being validated.  
The parameters that are affected by the changes in chromatographic conditions are, 
 Column capacity factor (KA) 
 Resolution (Rs) 
 Selectivity () 
 Column efficiency (N) and 
 Peak asymmetry factor (As) 
i) Column capacity factor (KA) 
The retention of a drug with a given packing material and eluent can be expressed as 
retention time or retention volume, but both of these are dependent on flow rate, 
column length and column diameter. The retention is best described as a column 
capacity ratio (K), which is independent of these factors. The column capacity ratio of 
a compound (A) is defined as  
0
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0
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Where, 
VA = Elution volume of A 
V0 = Elution volume of a non retained compound (void volume). 
ii) Resolution (Rs) 
The resolution, Rs of two neighboring peaks is defined by the ratio of the distance 
between the two peak maxima. It is the difference between the retention times of two 
solutes divided by their average peak width. For baseline separation, the ideal value of 
Rs is 2.0. It is calculated by using the formula, 
)WW(5.0
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Where,  
Rt1 and Rt2 are the retention times of components 1 and 2  
W1 and W2 are peak widths of components 1 and 2.          
iii)  Selectivity () 
The selectivity (or separation factor), , is a measure of relative retention of two 
components in a mixture. The ideal value of selectivity is 2. It can be calculated by 
using the formula,   
01
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Where, V0 is the void volume of the column and V2 and V1 are the retention    
volumes of the second and the first peak, respectively.            
iv) Column efficiency 
Efficiency, N, of a column is measured by the number of theoretical plates per meter. 
It is a measure of band spreading of a peak. Smaller the band spread, higher is the 
number of theoretical plates, indicating good column and system performance. 
Columns with N ranging from 5,000 to100,000 plates/meter are ideal for a good 
system. Efficiency is calculated by using the formula, 
 
2
2
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N   
Where, Rt is the retention time and W is the peak width. 
v) Peak asymmetry factor (As) 
Peak asymmetry factor, As can be used as a criterion of column performance. The 
peak half width b of a peak at 10 % of the peak height, divided by the corresponding 
front half width a gives the asymmetry factor.                                       
vi) Tailing factor (T) 
A measure of the symmetry of a peak. 
                                              T = W0.05 / 2f  
 Where,  
               W0.05 -peak width at 5% height  
               f -distance from peak front to apex point at 5% height.  
 The accuracy of quantification decreases with increase in peak tailing because 
of the difficulties encountered by the integrator in determining where/when the peak 
ends and hence the calculation of the area under the peak.  
Limits-T </= 2 
 
STATISTICAL PARAMETERS
13, 14 
Regression equations 
               The linear relationship is characterized by attendancy of the points of the scattered 
diagram to cluster along a straight line, known as the regression line. 
                                       Y= a + bX 
         It is used to describe the dependence of one characteristic (Y) up on the other 
characteristic (X), both X,Y represent values of two characters, a and b  are two constants it 
will be evident that two regression lines can be computed for every set of data-one each to 
describe the dependence of one character to another. b is known as regressive coefficients 
which show change expected in Y for unit change in X, it is dependence of Y & X; b is the 
regressive coefficient of Y& X.  
The regressive coefficient of b is estimated,  
                                                
b = the slope of the regression line and is calculated by this formula 
 x = an arbitrarily chosen value of the predictor variable for which the corresponding value 
of the criterion variable is desired. 
Correlation coefficient 
A measure of the strength of the relationship between two variables is provided by the 
coefficient of correlation, denoted by r, if the relationship between the two variables is of 
the linear form. It is also called the coefficient of linear correlation. 
Standard deviation 
It is the square root of the average of the squared deviations of the observations. From the 
arithmetic mean, it is used for measures of dispersion. 
It is denoted by         
                    Standard Deviation     =    
1
)( 2


n
xx
 
          
                       R.S.D (%)                =        100
x
S.D
   
Where, 
               = Sum of observations 
   x              = Mean or arithmetic average (x / n) 
   x               = Individual observed value 
  x –    x             = Deviation of a value from the mean 
   n               = Number of observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                  AIM AND SCOPE OF THE WORK 
 
  The pharmaceutical formulations have gained a lot of importance in today’s world 
due to greater patient acceptability, increased potency, multiple action, fewer side effects 
and quick action. Simultaneous analysis procedures are now being used more frequently for 
analysis of drugs in pharmaceutical formulations due to their advantages i.e. less time 
consuming, economical, accurate and precise. 
The aim is development and validation of Metformin Hydrochloride (250mg) and 
Repaglinide (1mg) using parameters such precision, accuracy, linearity, specificity,    
robustness, ruggedness. Standard analytical procedure for newer drugs of formulation may 
not be available in pharmacopoeias; hence it is essential to develop newer analytical 
methods which are simple, accurate, precise, specific, economic, linear and rapid. 
  From the literature review it was found that a very few analytical methods have 
been reported for the simultaneous estimation of metformin hydrochloride and repaglinide 
by RP-HPLC. 
Therefore in the proposed project, a successful attempt has been made to develop 
simple, accurate, economic and rapid methods for the estimation of tablet formulation and 
to validate the methods, as a result three simple, economic, precise and accurate methods 
were developed and validated by Reverse Phase High performance Liquid Chromatography 
The method has been validated as per the guidelines given by ICH requirements to 
assure that the method consistently meets the predetermined specifications and quality 
attributes. 
 
 
 
PLAN OF WORK 
Literature survey 
Through survey available for metformin hydrochloride and repaglinide, regarding 
their physical and chemical properties, pharmacology, pharmacokinetics and reported 
analytical methods, forms the basis for the development of new RP-HPLC method for 
simultaneous analysis of these drugs were designed. 
Procurement of samples 
Procurement of the drugs specimens draws utmost priority. Both the drugs obtained 
from Chandra laboratories as samples and characterized by their melting points. 
Development of sample 
1. Selection of solvent system 
2. Selection of mobile phase 
3. Simultaneous method development for assay 
4. Analysis of the commercially available formulations. 
Analytical validations of development method according to ICH guideline parameters, 
which are selected for method validation, are as follows- 
1. Precision  
2. Linearity 
3. Accuracy 
4. Robustness 
5. Ruggedness  
6. System precision 
 
1. METFORMINE HYDROCHLORIDE15 
 
Molecular structure: 
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Molecular weight             :         165.62 
Molecular formula           :         C4H12N5Cl 
Chemical name                :         1-carbamimidamido-N,N-dimethylmethanimidam  
HCl 
Category                          :         Hypoglycemic agent 
Description                      :         A white crystalline powder and highly hygroscopic 
Solubility                        :          Freely soluble in water, slightly soluble in alcohol, 
                                                 Practically insoluble in acetone, methylene chloride 
Melting point                   :         222
0
 C-226
0
 C 
Mechanism of action:           
Metformin's mechanisms of action differ from other classes of oral antihyperglycemic 
agents. Metformin decreases blood glucose levels by decreasing hepatic glucose 
production, decreasing intestinal absorption of glucose, and improving insulin 
sensitivity by increasing peripheral glucose uptake and utilization. These effects are 
mediated by the initial activation by metformin of AMP-activated protein kinase, a 
liver enzyme that plays an important role in insulin signaling, whole body energy 
balance, and the metabolism of glucose and fats. Activation of AMP-activated protein 
kinase is required for metformin's inhibitory effect on the production of glucose by 
liver cells. Metformin administration also increases AMP-activated protein kinase 
activity in skeletal muscle. AMP-activated protein kinase is known to cause GLUT4 
deployment to the plasma membrane, resulting in insulin-independent glucose uptake.  
Pharmacodynamics:  
Metformin is an oral antihyperglycemic agent that improves glucose tolerance in 
patients with NIDDM, lowering both basal and postprandial plasma glucose. 
Metformin is not chemically or pharmacologically related to any other class of oral 
antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce 
hypoglycemia in either patients with NIDDM or healthy subjects and does not cause 
hyperinsulinemia. Metformin does not affect insulin secretion. 
Pharmacokinetics:  
Metformin is metabolized. It is cleared from the body by tubular secretion and 
excreted unchanged in the urine, metformin id undetectable in blood plasma within 24 
hrs of a single oral dose. 
Adverse effects: Nausea, vomiting, anorexia, lactic acidosis, tolerance. 
Contraindications: Diabetic ketoacidosis, cardiovascular collapse, renal failure, 
hepatic failure. 
Special precautions: Alcohols not to be taken as an interaction occurs with 
metformin 
Half-life: 6.2 hours 
Dosage                         
For adults, the initial dose is 250 mg twice or thrice a day with meals and increases 
gradually at 2 weeks intervals. 
Storage                        
 In a well closed container, stored at room temperature. 
 
 2. REPAGLINIDE16 
 
Molecular structure: 
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Molecular formula           :     C27H36N2O4 
Molecular weight              :      452.58 
Chemical name                  :        2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-    
                                                       yl)phenyl]butyl]carbamoyl}methyl)benzoic acid 
Category                            :       Hypoglycemic acid 
Description                         :        A white crystalline powder and highly hygroscopic  
Solubility                            :       Freely soluble in methanol.  
Melting point                     :        130-131
0
 C 
Mechanism of action:  
 Repaglinide activity is dependent on the presence functioning β cells and glucose. In 
contrast to sulfonylurea insulin secretatogogues, repaglinide has no effect on insulin 
release in the absence of glucose. Rather, it potentiates the effect of extracellular 
glucose on ATP-sensitive potassium channel and has little effect on insulin levels 
between meals and overnight. As such, repaglinide is more effective at reducing 
postprandial blood glucose levels than fasting blood glucose levels and requires a 
longer duration of therapy (approximately one month) before decreases in fasting 
blood glucose are observed. The insulinotropic effects of repaglinide are highest at 
intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release 
already stimulated by high glucose concentrations (greater than 15 mmol/L). 
Repaglinide appears to be selective for pancreatic β cells and does not appear to 
affect skeletal or cardiac muscle or thyroid tissue. 
 Pharmacodynamic:  
Insulin secretion by pancreatic β cells is partly controlled by cellular membrane 
potential. Membrane potential is regulated through an inverse relationship between 
the activity of cell membrane ATP-sensitive potassium channels (ABCC8) and 
extracellular glucose concentrations. Extracellular glucose enters the cell via GLUT2 
(SLC2A2) transporters. Once inside the cell, glucose is metabolized to produce ATP. 
High concentrations of ATP inhibit ATP-sensitive potassium channels causing 
membrane depolarization. When extracellular glucose concentrations are low, ATP-
sensitive potassium channels open causing membrane repolarization. High glucose 
concentrations cause ATP-sensitive potassium channels to close resulting in 
membrane depolarization and opening of L-type calcium channels. The influx of 
calcium ions stimulates calcium-dependent exocytosis of insulin granules. 
Repaglinide increases insulin release by inhibiting ATP-sensitive potassium channels 
in a glucose-dependent manner. 
Pharmacokinetic:  
Absorption- Rapid and complete; peak plasma concentrations after 1 hour (oral). 
Distribution-Protein-binding :> 98%. 
Metabolism-Completely metabolized by oxidative biotransformation and direct  
Conjugation with glucuronic acid. 
Excretion-Urine (about 8%); feaces (90%) 
Adverse effects:  
  Hypoglycaemia, nausea, diarrhoea, constipation, vomiting, dyspepsia, arthralgia,     
Sinusitis, rhinitis, back pain; rash, pruritus, urticaria; visual disturbances. 
Contraindications 
Diabetic ketoacidosis; severe hepatic impairment, type 1 diabetes; hypersensitivity. 
Lactation. 
Special precautions 
Myocardial infarction, coma, trauma during surgery, elderly, malnourished and 
debilitated patients. Hepatic or severe renal impairment. Pregnancy. 
Half-life: 1 hour 
Dosage 
Adult: Usual initial dose: 0.5 mg, taken within 30 minutes of main meals. Initial doses 
of 1 or 2 mg may be used in patients who have had previous hypoglycemic treatment. 
May adjust dose at intervals of 1-2 weeks, up to 4 mg before meals. 
 Storage:  
 Store below 25°C. Protect from moisture. 
 
 
 
 
 
 
 
 
LITERATURE REVIEW 
Reported methods for Metformin hydrochloride 
1) Bhaskar Laxmanrao Kolte et al17 A simple, rapid, and precise reversed-phase liquid 
chromatographic method has been developed for the simultaneous determination of 
metformin in combination with glimepride. Under the developed conditions, good 
separation of the analytes was achieved in short analysis time. Several parameters 
affecting the separation of the analytes were studied, including pH and the 
concentration of SDS. The method is validated and shown to be linear in the range of 
25 μg/mL to 150 μg/mL for metformin and 0.1 μg/mL to 0.6 μg/mL for glimepride. 
The method is applied for the analysis of these analytes in commercially available 
tablets. 
2) Aryane MS et al., 200618 and coworkers carried out the development and validation 
of RP-HPLC method for the analysis of Metformin. In this a simple RP-HPLC 
method was developed for the quantification of Metformin hydrochloride in raw 
materials and in pharmaceutical preparations.  Analytical Reverse Phase Column 
C(18) was used and the mobile phase consisted of methanol-water(30/70v/v) the 
analytes were then determined by using UV detector.  This method was validated 
according to ICH guidelines. The proposed method is rapid, accurate, economical and 
selective and it was used for the quantitative analysis of metformin in Neodipar 
tablets because of its sensitivity and reproducibility. 
3) Sahoo P.K. et al., 200819, A high performance reverse phase liquid chromatographic 
procedure is developed for simultaneous estimation of metformin hydrochloride and 
pioglitazone hydrochloride in combined tablet dosage form. The mobile phase used 
was a combination of acetonitrile:water:acetic acid (60:40:0.3) and the pH was 
adjusted to 5.5 by adding triethylamine. The detection of the combined dosage form 
was carried out at 230 nm and a flow rate employed was 1 ml/min. Linearity was 
obtained in the concentration range of 0.015 to 0.120 mg/ml of pioglitazone 
hydrochloride and 0.5 to 4.0 mg/ml of metformin hydrochloride with a correlation 
coefficient of 0.9992 and 0.9975. The results of the analysis were validated 
statistically and recovery studies confirmed the accuracy and precision of the 
proposed method. 
4) Sadaf Sayeed et al., 200920, A simple, accurate and economic simultaneous equation 
method has been described for the simultaneous determination of metformin and 
pioglitazone in tablet dosage formulations. Metformin and pioglitazone showed 
absorption maxima at 233.5 nm and 266.5 nm respectively in 0.1 M NaOH prepared 
in glass double distilled water. The method allows rapid analysis of binary 
pharmaceutical formulations with high degree of accuracy and precision. Both the 
drugs showed linearity with absorbance in the concentration ranges, 5-40 mg / ml for 
Metformin and 10-80 mg / ml for pioglitazone. The results of the analysis have been 
validated statistically and by recovery studies. The method was also extending for 
dissolution studies. 
5) Mousumi kar et al., 200921, simple, accurate, economical and reproducible HPLC 
method has been developed for quantitative estimation of metformin hydrochloride 
from tablet dosage form and formulated microspheres. The developed HPLC method 
is a reverse phase chromatographic method using phenomenex C18 column and 
acetonitrile:phosphate buffer (65:35) pH adjusted to 5.75 with o-phosphoric acid as 
mobile phase and glipizide as internal standard. The linearity was observed in 
concentration range of 0-25 μg/ml for metformin hydrochloride. Results of analysis 
were validated statistically and by recovery studies. 
6) Lakshmi K.S. et al.,200922, reported a simple, sensitive and rapid reverse phase high 
performance liquid chromatographic method was developed for the estimation of 
Metformin Hcl and Pioglitazone in pure and in pharmaceutical dosage forms. A 
Gemini C18 column (150x4.6mm, 5μ) was used with a mobile phase containing a 
mixture of Acetonitrile and Ammonium Acetate buffer (pH-3) in the ratio of 42: 58. 
The flow rate was 0.3ml/min and effluents were monitored at 255nm and eluted at 
5.17min and 8.1min .Calibration curve was plotted with a range from 0.5-50 μg/ml for 
Metformin HCl and 0.3-30 μg/ml for Pioglitazone. The assay was validated for the 
parameters like accuracy, precision, robustness and system suitability parameters. The 
proposed method can be useful in the routine analysis for the determination of 
metformin and pioglitazone in pharmaceutical dosage forms. 
7) Onal A. et al, 200923, carried out spectrophotometric and HPLC determinations of 
anti-diabetic drugs, Rosiglitazone maleate and Metformin hydrochloride, in pure form 
and in pharmaceutical preparations.  In this method he developed three Spectrometric 
method and one HPLC method for analysis of Anti-diabetic drugs.  Two 
Spectrometric methods were based on the reaction of rosiglitazone with 2,3-dichloro-
5,6-dicyano-1,4-benzoquinone and bromocresol green, the third Spectrophotometric 
method consists of a zero-crossing first-derivative Spectrophotometric method for 
simultaneous analysis of RSG and metformin in tablets.  The fourth method is a rapid 
stability indicating HPLC method.  The proposed method was successfully applied to 
the tablet analysis. 
8) Narsimha rao Doredla et al, 201124 developed a simultaneous estimation of 
Metformin HCl, pioglitazone HCl and glibenclamide in pure and tablet dosage form 
by using methanol as a solvent. Metformin HCl, pioglitazone HCl and glibenclamide 
show absorbance maxima at 237 nm, 270 nm and 230 nm respectively. Shimadzu UV 
1700, capable of multicomponent analysis, was used for quantitation. This method is 
based on a multiwavelength spectroscopic method. Validation study reveals that the 
methods are specific, accurate, precise, and reproducible. All three drugs obey Beer's 
law in the concentration ranges used for the methods. Validation studies are 
statistically significant as all the statistical parameters are within the acceptance range 
for both accuracy and precision study. The methods are simple, rapid accurate, 
precise, reproducible, and economic and can be used for routine quantitative analysis 
of Metformin HCl, pioglitazone HCl and glibenclamide in pure and tablet dosage 
form. 
9) Serasiya et al., 201125, developed a simple, precise, specific and accurate reverse 
phase HPLC method has been for the simultaneous estimation of enalapril maleate 
(EM) and metformin hydrochloride (MT). The chromatographic separation was 
achieved on phenomenex Luna C18 (25 cm Ã— 4.6 mm i.d., 5 Âµ) column using 
PDA detector. The mobile phase consisting of mixture of acetonitrile - 10mM 
NaH2PO4 (pH 2.2, adjusted with 80 % o-phosphoric acid) (30:70, v/v) at a flow rate of 
1.0 ml/min was used. The method was validated according to the ICH guidelines with 
respect to specificity, linearity, accuracy, precision and robustness. 
10) Angshuman Biswas et al., 201126, A new simple, fast accurate and reproducible 
reverse phase high performance liquid chromatographic method has been developed 
and validated for simultaneous estimation of Metformin Hydrochloride and 
Glimepiride from tablet dosage form. The method was developed using Waters HPLC 
system on C18 column (Spherisorb ODS 2: 250mm x 4.6 μm) using a mixture of 
25mM Phosphoric Acid pH 3.0 (with KOH) and Acetonitrile (40:60 v/v) as mobile 
phase in an isocratic elution mode at a flow rate of 1.00 ml/min at 40ºC with a load of 
20μl. The detection was carried out using UV-Visible detector set at 240 nm. The 
retention time of Metformin Hydrochloride and Glimepiride were found to be 3.20 
min and 6.7 min respectively. The method was validated with respect to linearity, 
robustness, precision and accuracy. The method had been successfully applied in 
other pharmaceutical formulations of the same composition. 
11) Bhaskar Reddy et al., 201127, Novel RP-HPLC method has been developed for 
simultaneous determination of Meformin HCl, Glipizide and Repaglinide in dosage 
forms. The separation was achieved on a 3.5-micron C18 column (150 X 4.6 mm) 
using mobile phase consisting of buffer (1.0gm of Potassium dihydrogen phosphate in 
1000mL, pH 3.0 with diluted orthophospharic acid .The flow rate was maintained at 
1.0 ml/min. The detection of the constituents was done using UV detector at 210 nm. 
The retention time of metformin, glipizide and repaglinide were approximately 1.49, 
3.71 and 9.84 min respectively. Recovery study values of three actives were 103% to 
99% respectively, relative standard deviation of less than 2%. Linear response 
obtained for three actives correlation coefficient is not less than 0.999. The proposed 
method was applied for  
regular analysis and results found to be satisfactory. 
12) Bhamare P.C. et al., 201128, reported a selective, precise, isocratic and accurate 
stability indicating reverse phase high performance liquid chromatography method 
have been developed for the simultaneous determination of Metformin hydrochloride 
and Fenofibrate present in multicomponent dosage forms. The HPLC method was 
carried out on Inertsil octadecylsilane C18 (250 mm x 4.6 mm i.d., 5 μm particle size) 
column. A mobile phase composed of acetonitrile - water (adjusted to pH 3 using 
orthophosphoric acid) in proportion of 70:30 v/v, at flow rate of 1 ml/min was used 
for the separation. Detection was carried out at 250nm. Method was validated 
statistically and recovery studies were carried out. The proposed method has been 
applied successfully to the analysis of cited drugs either in pure form or in 
pharmaceutical formulations with good accuracy and precision. The method herein 
described can be employed for quality control and routine analysis of drugs in 
pharmaceutical formulations. 
Reported methods for repaglinide 
1) Venkatesh P. et al., 200629, this paper describes a convenient method for the 
separation and simultaneous determination of six anti-diabetic drugs viz., 
glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone  in 
pharmaceutical formulations. Also, the assay has been shown applied to support 
quantification of the six anti-diabetic drugs in human plasma. The analytes were 
either injected directly onto the column after suitable dilution (pharmaceutical 
formulation analysis) or a simple extraction procedure, using acetonitrile, from human 
plasma spiked with anti-diabetic drugs and internal standard (IS). Ternary gradient 
elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 
x 250 mm, 5 microm) at ambient temperature. The mobile phase consisted of 0.01 m 
formic acid (pH 3.0), acetonitrile, Milli Q water and methanol. Celecoxib was used as 
an IS. The six anti-diabetic drugs were monitored at a wavelength of 260 nm. The 
nominal retention times of glibenclamide, gliclazide, glipizide, pioglitazone, 
repaglinide and rosiglitazone were 11.4, 13.3, 14.8, 17.6, 20.78, 22.1 and 25.4 min, 
respectively. The assay developed for formulation analysis was found to be accurate 
and precise. The calibration curves ranged from 0.1 to 100 microg/mL for all analytes 
with the exception of GLB, where the range was 0.3-100 microg/mL. The plasma 
assay was validated for parameters such as specificity, accuracy and extraction 
recovery. The proposed method is simple, selective and can be extended for routine 
analysis of anti-diabetics in pharmaceutical preparations and in biological matrices. 
2) Kaushal N. et al., 201030, Spectrofluorimetric and high-performance liquid 
chromatography methods for estimation of repaglinide were developed. These 
methods were validated for estimation of repaglinide in tablets as well as in receptor 
fluid obtained during in vitro permeation studies. Repaglinide was observed to exhibit 
emission and excitation wavelengths, respectively, at 379 nm and 282 nm with 
linearity in the concentration range of 5-80 µg/ml. High-performance liquid 
chromatography analysis of repaglinide yielded retention time of 6.14 min with 
linearity ranging from 0.1-1.2 µg/ml concentration. Spectrofluorimetric analysis of 
repaglinide in tablets yielded results comparable to high performance liquid 
chromatography. 
3) Love kumar soni et al., 201231, A simple, rapid and specific reversed-phase high 
performance liquid chromatographic method for simultaneous analysis of metformin 
hydrochloride, and repaglinide in a tablet dosage form has been developed and 
validated. HPLC analysis was performed on a C18 column with  90:10 (v/v) 
acetonitrile – water as mobile phase at a flow rate of 1.0 mL min-1. UV detection was 
performed at 223 nm.  Total run time was 10 min; metformin hydrochloride and 
repaglinide were eluted with retention times of 2.72 min and 6.13min, respectively. 
The method was validated for accuracy, precision, linearity, specificity, and 
sensitivity in accordance with ICH guidelines. Validation revealed that the method is 
specific, rapid, accurate, precise, reliable, and reproducible. The high recovery and 
low coefficients of variation confirmed the suitability of the method for simultaneous 
analysis of the two drugs in tablet dosage form. 
4) Deepa R. et al32., A simple, specific and accurate stability-indicating reversed phase 
high performance liquid chromatographic method was developed for the simultaneous 
determination of Repaglinide and Metformin hydrochloride. An isocratic RPHPLC 
was achieved on younglin HPLC system using Varian C18 (250 -4.6 mm i.d, 5 m 
particle size) columnwith the mobile phase containing mixture of acetonitrile: 10mM 
ammonium acetate(pH 3.0, adjusted with phosphoric acid) (70 : 30, v/v). The flow 
rate was 1.0ml/min and the eluent was monitored at 230nm. The retention times of 
Repaglinide and Metformin hydrochloride were found to be 3.1 min and 5.58 min, 
respectively. Linearity was established for Repaglinide and Metformin hydrochloride 
in the range of 0.5-3 µg/ml and 200-1200 µg/ml, respectively. The percentage 
recoveries of Repaglinide and Metformin hydrochloride were found to be in the range 
of 99.87%±0.7 and 99.89%±0.15 respectively. Both the drugs were subjected to acid, 
alkali, oxidation, and dry heat degradation. The degradation studies indicated, 
Repaglinide and Metformin hydrochloride showed degradation in acid, alkaline, 
H2O2, and in dry heat condition. The degradation products of Repaglinide and 
Metformin hydrochloride were well resolved from the pure drug with significant 
differences in their retention time values. This method can be successfully employed 
for simultaneous quantitative analysis of Repaglinide and Metformin hydrochloride in 
bulk drugs and formulations. 
 
 
 
 
 
 
 
 
 
 
4.1 MATERIALS 
Drug sample  
 Metformin hydrochloride and repaglinide sample obtained from Chandra labs Pvt., 
Ltd., Hyderabad.                                                                                                                              
 Formulation used 
              Prandimet tablets containing 500 mg metformin hydrochloride and 2 mg 
repaglinide were proceed from Chandra labs Pvt., Ltd., Hyderabad. 
Equipement used: 
S.No  Name Model  Manufacturer/Supplier 
1. Analytical balance Unibloc Shimadzu, Libror 
2. pH meter Eutech  Shimadzu. 
3. HPLC LC-2010 Shimadzu Corporation, Japan 
4. UV UV-2550 Shimadzu Corporation 
 
Chemicals used: 
S.No Chemicals Grade Manufacturer/Supplier 
1. Water  HPLC Microlabs 
2. Methanol  HPLC Merck  
3. Acetonitrile  HPLC Merck  
4. Potassium dihydrogen phosphate AR Merck  
5. Sodium dihydrogen phosphate AR Merck  
6. 0.1M Sodium hydroxide AR Merck  
7. Hydrochloric acid AR Merck  
8. Triethylamine  AR Spectrochem 
9. Ortho phosphoric acid AR Merck  
 
 
 
METHOD DEVELOPMENT 
A method was developed for the determination of repaglinide and metformin HCl on HPLC 
by selecting the solubility, λmax and optimum mobile phase which gives good resolution of 
repaglinide and metformin HCl. 
SOLUBILITY 
 Solubility of drugs was observed by dissolving it in different solvents and it was found that     
 drugs having good solubility in following solvents. 
Table 1: Solubility of drugs in different solvents 
 
S.no 
  
      Solvent 
                               Solubility 
Metformin Hydrochloride  Repaglinide  
1. Water + + 
2. Acetonitrile + + 
3. 0.1N NaOH + + 
4. 0.1N HCl + + 
5. Methanol + + 
 
SELECTION OF WAVELENGTH (λmax) 
Standard stock solution of repaglinide 
 Accurately 10 mg of  repaglinide was weighed into a clean and dry 10 ml volumetric 
flask, dissolved with sufficient volume of mobile phase and then made up to the 
volume with mobile phase. 
Working standard solution 
0.1 ml of the stock solution was further diluted in a 10 ml volumetric flask with 
mobile phase to get a concentration of 10 µg/ml. 
 
Standard stock solution of Metformin Hydrochloride 
Accurately 10 mg of  Metformin HCl was weighed into a clean and dry 10 ml 
volumetric flask, dissolved with sufficient volume of mobile phase and then made up 
to the volume with mobile phase. 
Working standard solution 
0.1 ml of the stock solution was further diluted in a 10 ml volumetric flask with 
mobile phase to get a concentration of 10 µg/ml. 
The overlaid UV spectrum of Metformin and Repaglinide was represented in fig-2. 
FIGURE-2 
OVERLAID UV SPECTRUM OF REPAGLINIDE AND METFORMIN 
HYDROCHLORIDE 
 
 
INITIALIZATION OF THE INSTRUMENT 
Initially, the column was placed on the instrument and switch on the instruments and washed 
with methanol: water (20:80) for 30 min. then the system was made to run with the mobile 
phase for 30 min for column saturation. 
Standard preparation of Metformin HCl and Repaglinide 
Standard-A: Accurately weighed quantity of 500 mg metformin HCl was transferred in to a 
100 ml volumetric flask and made up to the volume with diluents. From this 5 ml was 
pipetted out in to a 50 ml volumetric flask and made up to the volume with same diluents. 
Standard-B: Accurately weighed quantity of 2 mg repaglinide was transferred in to a 100 ml 
volumetric flask and made up to the volume with diluents. From this 5 ml was pipetted out 
in to a 50 ml volumetric flask and made up to the volume with same diluents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRAIL-1 
1. Preparation of Buffer: 
0.01mole of potassium dihydrogen phosphate was dissolved in 1000ml of water and 
adjust the pH-3 using diluted O-phosphoric acid. 
2. Preparation of mobile phase: 
Filtered and degassed mixture of acetonitrile: buffer in the ratio of 80:20 and filter 
through 0.45 micron membrane filter (Fig-3). 
Fig: 3 Metformin HCl and Repaglinide 
 
Observation: Assymetry of metformin HCl was not good. 
 
 
TRAIL-2 
1. Preparation of Buffer: 
0.01mole of potassium dihydrogen phosphate was dissolved in 1000ml of water and 
adjust the pH-3 using diluted O-phosphoric acid. 
2. Preparation of mobile phase: 
Filtered and degassed mixture of acetonitrile: buffer in the ratio of 60:40 and filter                
through 0.45 micron membrane filter (Fig- 4). 
Fig: 4 Metformin HCl and Repaglinide 
 
Observation: Retention time of metformin HCl was not good. 
 
 
TRAIL-3 
1. Preparation of Buffer: 
0.01mole of potassium dihydrogen phosphate was dissolved in 1000ml of water and adjust 
the pH-3 using diluted O-phosphoric acid. 
2. Preparation of mobile phase: 
Filtered and degassed mixture of acetonitrile: buffer in the ratio of 50:50 and filter through 
0.45 micron membrane filter (Fig-5). 
Fig: 5 Metformin HCl and Repaglinide 
 
Observation: 
Retention time of metformin HCl was not good. 
 
TRAIL-4 
1. Preparation of Buffer: 
0.01mole of sodium dihydrogen phosphate was dissolved in 1000ml of water and adjust the 
pH-3 using diluted O-phosphoric acid. 
2. Preparation of mobile phase: 
Filtered and degassed mixture of acetonitrile: buffer in the ratio of 60:40 and filter through 
0.45 micron membrane filter (Fig-6). 
Fig: 6 Metformin HCl and Repaglinide 
 
Observation: Retention time of metformin HCl was not good. 
 
 
OPTIMIZED METHOD 
1. Preparation of Buffer: 
0.01mole of sodium dihydrogen phosphate was dissolved in 1000ml of water and adjust 
the pH-3 using diluted O-phosphoric acid. 
2. Preparation of mobile phase: 
Filtered and degassed mixture of acetonitrile: buffer in the ratio of 58:42 and filter through 
0.45 micron membrane filter. 
3. Preparation of standard stock solution   
An accurately weighed quantity of  500 mg of Metformin HCl and 2 mg of 
Repaglinide was transferred into 100 ml volumetric flask, dissolve  in about 15 ml of 
mobile phase sonicate about 10 min until all the content has been dissolved, then the 
volume was made up to the mark with mobile phase. The concentrations of 
Metformin HCl and Repaglinide were found to be 5000 µg/ml and 20 µg/ml. 
4. Preparation of sample solution 
Weigh about 20 tablets and powdered. From that an equivalent amount of 500 mg of 
Metformin HCl and 1 mg of Propranolol hydrochloride was taken into 100 ml 
volumetric flask. Add about 10 ml of mobile phase and sonicate until the content was 
dissolved. Filter the content by using 0.45µ membrane filter by applying vacuum. 
Made the volume up to the mark with the mobile phase (Fig-7). 
 
 
 
 
 
Table 2: Optimized Chromatographic Condition 
 
Parameters  Description   
Mode of operation Isocratic 
Diluents  Water 
Column  C18, 250x4.6mm,5µ SS column 
Mobile phase Acetonitrile: buffer (58:42) 
Flow rate 1.0 ml/min 
Detection of Metformin HCl and repaglinide 230 nm 
Temperature  25
0
 C 
Injection Volume 20 µl 
Run time 20 min 
Detector  UV detector 
 
 
 
 
 
 
 
 
 
Fig: 7 Metformin HCl and Repaglinide 
 
Observation: The retention time of Metformin HCl was 2.1 and Repaglinide was found to 
be 6.0 min. Theoretical plates, asymmetry are within the limits. 
Conclusion 
             Out of the trials which were performed, the 5
th
 trial was selected as the 
optimized condition for the method development, because the retention time was 
good, the asymmetry was found to be within the limits, the resolution was good. 
 
 
 
 
 
VALIDATION OF DEVELOPED RPHPLC METHOD FOR SIMULTANEOUS 
ESTIMATION OF REPAGLINIDE AND METFORMIN HCL 
Since the HPLC method has been developed, validation of method using various 
parameters was performed to ensure that the performance characteristic of the method 
meets the requirements for the intended analytical applications. 
I.SYSTEM SUITABILITY 
System suitability studies 
From the standard solution of Repaglinide and Metformin hydrochloride five 
replicated injections were made. Various system suitability parameters like plate 
number (N), asymmetry factor, retention time, resolution, tailing factor, were 
evaluated from the standard chromatogram. 
Blank solution: Purity water was used as diluents. 
Preparation of standard solution: 
An accurately weighed quantity of  500 mg metformin and 2 mg repaglinide was transferred 
into 100 ml volumetric flask, dissolved in about 15 ml of mobile phase and sonicated about 
10 min until all the content has been dissolved, then the volume was made up to the mark 
with mobile phase. 
Preparation of test solution: 
About 0.819 g of the sample was taken in 100 ml volumetric flask and added 15 ml of 
mobile phase and sonicated for 15 min to dissolve the content and made upto the 
volume. From this 5 ml was pipette out into 100 ml volumetric flask and made upto 
the volume with same mobile phase. Filter the content by using 0.45µ membrane filter 
by applying vacuum (Fig-8). The results are tabulated in Table. No.-3 
 
Fig: 8 Metformin HCl and Repaglinide 
 
II. SPECIFICITY 
For the simultaneous determination of Metformin HCl and Repaglinide, the 
specificity requires that the method should not be affected by the presence of other 
components. Usually the specificity would be performed by allowing the sample 
under stressed conditions. 
a) Treating with Acids 
Take 1 ml from the stock solution into a 10 ml flask. To that flask add 1 ml of 
0.1M hydrochloric acid. Observe for any change took place in the retention of the 
peak    (Fig-9) 
 
 b) Treating with Base 
Take 1 ml from stocks solution into a 10 ml flask, and add 1 ml of 0.1 M sodium 
hydroxide. Observe for any degradedness. (Fig-10) 
c) Heating  
For the specificity study 1 ml from the stock solution should be taken in a 10 ml 
flask, make up to the volume with the mobile phase. The solution should be 
heated at 40 
o
 for a period of 30 min. Observe for any degradation occurs or not. 
(Fig-11) 
III. LINEARITY 
Preparation of standard stock solution 
An accurately weighed quantity of  250 mg metformin and 1 mg repaglinide was 
transferred into 100 ml volumetric flask, dissolved in about 15 ml of mobile phase 
and sonicated about 10 min until all the content has been dissolved, then the volume 
was made up to the mark with mobile phase. 
Preparation of linearity solution-I: Pipette out 1ml from stock solution to 100 ml 
with mobile phase. The concentration of the solution becomes 25µg of metformin and 
0.1µg of repaglinide. (Fig-12) 
Preparation of linearity solution-II: Pipette out 2ml from stock solution to 100 ml 
with mobile phase. The concentration of the solution becomes 50µg of metformin and 
0.2µg of repaglinide. (Fig-13) 
Preparation of linearity solution-III: Pipette out 3ml from stock solution to 100 ml 
with mobile phase. The concentration of the solution becomes 75µg of metformin and 
0.3µg of repaglinide. (Fig-14) 
Preparation of linearity solution-IV: Pipette out 4ml from stock solution to 100 ml 
with mobile phase. The concentration of the solution becomes 100µg of metformin 
and 0.4µg of repaglinide. (Fig-15) 
Preparation of linearity solution-V: Pipette out 5ml from stock solution to 100 ml 
with mobile phase. The concentration of the solution becomes 125µg of metformin 
and 0.5µg of repaglinide. (Fig-16) 
Preparation of linearity solution-VI: Pipette out 6ml from stock solution to 100 ml 
with mobile phase. The concentration of the solution becomes 150µg of metformin 
and 0.6µg of repaglinide. (Fig-17) 
Determination: The linearity of the analytical method is determined by mathematical 
treatment of test results obtained by analysis of samples with analyte concentrations 
across the claimed range. Area is plotted graphically as a function of analyte 
concentration. Percentage curve fittings are calculated (Fig- 18). 
The results are tabulated in Table. No- 4&5. 
IV. ACCURACY 
Preparation of standard stock solution 
An accurately weighed quantity of  250 mg metformin and 1 mg repaglinide was transferred 
into 100 ml volumetric flask, dissolved in about 15 ml of mobile phase and sonicated about 
10 min until all the content has been dissolved, then the volume was made up to the mark 
with mobile phase. 
Preparation of Spiking standard: 5 ml from stock solution was further diluted into 
100 ml with mobile phase (Fig- 19, 20, 21). 
Preparation of Accuracy solution 1: Transfer 4ml from stock solution to 100 ml 
with mobile phase. The concentration of the solution becomes 112.5mcg of 
metformin and 0.4mcg of repaglinide and added 1 ml of spiking standard (Fig- 22, 23, 
24). 
Preparation of Accuracy solution 2: Pipette out 5ml from stock solution to 100 ml 
with mobile phase. The concentration of the solution becomes 137.5mcg of 
metformin and 0.5mcg of repaglinide and added 1 ml of spiking standard (Fig- 25, 26, 
27). 
Preparation of Accuracy solution 3: Pipette out 6ml from stock solution to 100 ml 
with mobile phase. The concentration of the solution becomes 162.5mcg of 
metformin and 0.6mcg of repaglinide and adds 1 ml of spiking standard (Fig- 28, 29, 
30).  
Determination:  the accuracy of an analytical method is determined by applying the 
method to analyzed samples, to which known amounts of analyte have been added. 
The accuracy is calculated from the test results as the percentage of analyte recovered 
by the assay. The accuracy studies for Repaglinide and Metformin HCl was carried 
out at three different levels (Fig-31). 
The results are tabulated in Table. No- 6&7. 
 
 
 
 
V. PRECISION  
A) Repeatability:  
Established the repeatability of the analytical method by estimating the assay for 5 sample 
proportion of the same batch under normal operating conditions. Calculated the assay for 
all 5 sample preparation and reported the %RSD for the same (Fig-32 to 36). 
Standard preparation: 
An accurately weighed quantity of  250 mg metformin and 1 mg repaglinide was transferred 
into 100 ml volumetric flask, dissolved in about 15 ml of mobile phase and sonicated about 
10 min until all the content has been dissolved, then the volume was made up to the mark 
with mobile phase. 
Preparation of test solution: 
About 0.819 g of the sample was taken in 100 ml volumetric flask and added 15 ml of 
mobile phase and sonicated for 15 min to dissolve the content and made upto the 
volume. From this 5 ml was pipette out into 100 ml volumetric flask and made up to 
the volume with same mobile phase. Filter the content by using 0.45µ membrane filter 
by applying vacuum. 
The results are tabulated in Table. No-8. 
B) Intermediate precision (ruggedness) 
Intermediate precision study was carried out by repeating the complete experiment 
with different analysts, on different days in same laboratory as per the following 
preparation. 
 
 
Standard preparation: 
An accurately weighed quantity of  250 mg metformin and 1 mg repaglinide was 
transferred into 100 ml volumetric flask, dissolved in about 15 ml of mobile phase 
and sonicated about 10 min until all the content has been dissolved, then the volume 
was made up to the mark with mobile phase. 
Preparation of test solution: 
About 0.819 g of the sample was taken in 100 ml volumetric flask and added 15 ml of 
mobile phase and sonicated for 15 min to dissolve the content and made upto the 
volume. From this 5 ml was pipette out into 100 ml volumetric flask and made upto 
the volume with same mobile phase. Filter the content by using 0.45µ membrane filter 
by applying vacuum (Fig-37&38). 
Determination: The precision of the analytical method and instrument is determined 
by assaying sufficient number of samples and relative standard deviation is calculated. 
The results are tabulated in Table. No-9. 
C) Method precision 
Standard preparation: 
An accurately weighed quantity of  250 mg metformin and 1 mg repaglinide was transferred 
into 100 ml volumetric flask, dissolved in about 15 ml of mobile phase and sonicated about 
10 min until all the content has been dissolved, then the volume was made up to the mark 
with mobile phase. 
Preparation of test solution: 
About 0.819 g of the sample was taken in 100 ml volumetric flask and added 15 ml of 
mobile phase and sonicated for 15 min to dissolve the content and made upto the 
volume. From this 5 ml was pipette out into 100 ml volumetric flask and made upto 
the volume with same mobile phase. Filter the content by using 0.45µ membrane filter 
by applying vacuum. (Fig-39 to 43) 
The results are tabulated in Table. No-10. 
VI. ROBUSTNESS 
Blank solution: Purity water was used as diluents. 
 Standard preparation: 
An accurately weighed quantity of  250 mg metformin and 1 mg repaglinide was 
transferred into 100 ml volumetric flask, dissolved in about 15 ml of mobile phase and 
sonicated about 10 min until all the content has been dissolved, then the volume was made 
up to the mark with mobile phase. 
Preparation of test solution: 
About 0.819 g of the sample was taken in 100 ml volumetric flask and added 15 ml of 
mobile phase and sonicated for 15 min to dissolve the content and made upto the 
volume. From this 5 ml was pipette out into 100 ml volumetric flask and made upto 
the volume with same mobile phase. Filter the content by using 0.45µ membrane filter 
by applying vacuum. (Fig-44-47) 
S. No Chromatographic 
condition 
Low  High  
1. Flow rate  0.9 ml 1.1 ml 
2. Wavelength  228 nm 232 nm 
 
Determination: the robustness of an analytical method is to determined by analysis 
of aliquots from homogenous lots by differing physical parameters that may differ but 
are still within the specified parameters of the assay.  
The results are tabulated in Table. No-11&12. 
ASSAY 
Weigh about 20 tablets and powdered. An equivalent weight of 500 mg and 2mg of 
Metformin HCl and Repaglinide were taken into 50 ml volumetric flask. Add about 
10 ml of mobile phase and sonicate until the contents were dissolved. Filter the 
contents by using 0.45µ membrane filter under vaccum. Make up to the mark with 
mobile phase. Inject 20µl of sample solution into the chromatographic system. 
Measure the area of Metformin HCl and Repaglinide and calculate the percentage of 
assay. 
Formula: 
=       Avg sample area x Standard wt x Tablet wt taken x Standard purity 
Avg std area x Sample wt x 100 
 
                         Assay % = Amount of sample  x   100 
                                           Label claim 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHROMATOGRAMS 
 
SPECIFICITY 
FIGURE – 9 
SPECIFICITY CHROMATOGRAM– I 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 0.1 M 
ACID 
 
 
 
 
 FIGURE – 10 
SPECIFICITY CHROMATOGRAM– II 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
0.1M NaOH 
 
 
 
 
 FIGURE – 11 
SPECIFICITY CHROMATOGRAM– III 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
HEATING 
  
 
 LINEARITY 
FIGURE – 12 
LINEARITY CHROMATOGRAM– I 
METFORMIN HYDROCHLORIDE (25 µg) AND REPAGLINIDE (0.10 µg) 
 
 
 
 
  
FIGURE – 13 
LINERARITY CHROMATOGRAM– II 
METFORMIN HYDROCHLORIDE (10 µg) AND REPAGLINIDE (0.04 µg) 
 
 
 
 
  
FIGURE – 14 
LINERARITY CHROMATOGRAM– III 
METFORMIN HYDROCHLORIDE (75 µg) AND REPAGLINIDE (0.3 µg) 
 
 
 
 
  
FIGURE – 15 
LINERARITY CHROMATOGRAM– IV 
METFORMIN HYDROCHLORIDE (100 µg) AND REPAGLINIDE (0.4 µg) 
 
 
 
 
 FIGURE – 16 
LINERARITY CHROMATOGRAM– V 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
  
FIGURE – 17 
LINERARITY CHROMATOGRAM– VI 
METFORMIN HYDROCHLORIDE (150 µg) AND REPAGLINIDE (0.6 µg) 
 
 
 
 
 
  
FIGURE – 18 
LINERARITY CHROMATOGRAM– I-IV 
METFORMIN HYDROCHLORIDE (150 µg) AND REPAGLINIDE (0.6 µg) 
 
 
 
 
 
 
  
                                                              ACCURACY 
FIGURE – 19 
SPIKING STANDARD CHROMATOGRAM – I 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
  
 
FIGURE – 20 
SPIKING STANDARD CHROMATOGRAM – II 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
  
 
FIGURE – 21 
SPIKING STANDARD CHROMATOGRAM – III 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
  
FIGURE – 22 
ACCURACY CHROMATOGRAM –TRIAL I (Solution-1) 
METFORMIN HYDROCHLORIDE (112.5 µg) AND REPAGLINIDE (0.45 µg) 
 
 
 
 
 
 
  
FIGURE – 23 
ACCURACY CHROMATOGRAM –TRIAL II (Solution-1) 
METFORMIN HYDROCHLORIDE (112.5 µg) AND REPAGLINIDE (0.45 µg) 
 
 
 
 
 
 
  
FIGURE – 24 
ACCURACY CHROMATOGRAM – TRIAL III (Solution-1) 
METFORMIN HYDROCHLORIDE (112.5 µg) AND REPAGLINIDE (0.45 µg) 
 
 
 
 
 
  
FIGURE – 25 
ACCURACY CHROMATOGRAM – TRIAL I (Solution-2) 
METFORMIN HYDROCHLORIDE (137.5 µg) AND REPAGLINIDE (0.55 µg)  
 
 
 
 
 
  
FIGURE – 26 
ACCURACY CHROMATOGRAM – TRIAL II (Solution-2) 
METFORMIN HYDROCHLORIDE (137.5 µg) AND REPAGLINIDE (0.55 µg) 
 
 
 
 
 
  
FIGURE – 27 
ACCURACY CHROMATOGRAM – TRIAL III (Solution-2) 
METFORMIN HYDROCHLORIDE (137.5 µg) AND REPAGLINIDE (0.55 µg) 
 
 
 
 
 
  
FIGURE – 28 
ACCURACY CHROMATOGRAM – TRIAL I (Solution-3) 
METFORMIN HYDROCHLORIDE (162.5 µg) AND REPAGLINIDE (0.65 µg) 
 
 
 
 
 
  
FIGURE – 29 
ACCURACY CHROMATOGRAM – TRIAL II (Solution-3) 
METFORMIN HYDROCHLORIDE (162.5 µg) AND REPAGLINIDE (0.65 µg) 
 
 
 
 
 
  
FIGURE – 30 
ACCURACY CHROMATOGRAM – TRIAL III (Solution-3) 
METFORMIN HYDROCHLORIDE (162.5 µg) AND REPAGLINIDE (0.65 µg) 
 
 
 
 
 
 
 
  
FIGURE – 31 
ACCURACY CHROMATOGRAM – TRIAL IV (Solution -3) 
METFORMIN HYDROCHLORIDE (162.5 µg) AND REPAGLINIDE (0.65 µg) 
 
 
 
 
  
  
PRECISION 
FIGURE – 32 
PRECISION CHROMATOGRAM– I 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg)  
 
  
 
 
  
FIGURE – 33 
PRECISION CHROMATOGRAM– II 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
  
 
 
  
FIGURE – 34 
PRECISION CHROMATOGRAM– III 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
 
 
  
FIGURE – 35 
PRECISION CHROMATOGRAM– IV 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
  
 
 
 
  
FIGURE – 36 
PRECISION CHROMATOGRAM– V 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
 
  
RUGGEDNESS 
 FIGURE – 37 
RUGGEDNESS CHROMATOGRAM– I 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg)  
 
 
 
 
  
FIGURE – 38 
RUGGEDNESS CHROMATOGRAM– II 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg)  
 
 
  
 
 
  
FIGURE – 39 
METHOD PRECISION CHROMATOGRAM– I 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
 
  
 FIGURE – 40 
METHOD PRECISION CHROMATOGRAM– II 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
  
 
 
 
  
FIGURE – 41 
METHOD PRECISION CHROMATOGRAM– III 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
  
 
 
 
  
FIGURE – 42 
METHOD PRECISION CHROMATOGRAM– IV 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
 
  
FIGURE – 43 
METHOD PRECISION CHROMATOGRAM– V 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
 
  
ROBUSTNESS 
FIGURE – 44 
ROBUSTNESS CHROMATOGRAM– I 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) AT 228 
nm 
  
 
  
FIGURE – 45 
ROBUSTNESS CHROMATOGRAM– II 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) AT 232 
nm 
 
 
 
 
  
FIGURE – 46 
ROBUSTNESS CHROMATOGRAM– III 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 1.1 ml 
flow 
 
 
 
 
  
FIGURE – 47 
ROBUSTNESS CHROMATOGRAM– IV 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 0.9 ml 
flow 
 
 
 
 
  
ASSAY 
FIGURE – 48 
ASSAY CHROMATOGRAM FOR STANDARD – I 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
  
 
FIGURE – 49 
ASSAY CHROMATOGRAM FOR STANDARD– II 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
 
  
FIGURE – 50 
ASSAY CHROMATOGRAM FOR STANDARD– III 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
 
  
FIGURE – 51 
ASSAY CHROMATOGRAM FOR SAMPLE – I 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
 
FIGURE – 52 
ASSAY CHROMATOGRAM FOR SAMPLE – II 
METFORMIN HYDROCHLORIDE (125 µg) AND REPAGLINIDE (0.5 µg) 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
SYSYEM SUITABILITY PARAMETERS:  
Table no-3: System suitability parameter for Metformine HCl and Repaglinide 
 
S. no 
 
     Parameters  
 
Repaglinide 
 
  Metformin hydrochloride 
 
 1. 
 
Resolution 
      
                           20.07 
 
 2. 
 
AUC 
 
24.459 
 
             106.384 
 
 3. 
 
No of theoretical plates 
   
         7188 
  
              5975 
 
 4. 
 
Retention time 
 
          6.003 
 
              2.060 
 
5. 
 
Asymmetry 
 
1.093 
 
                1.059 
 
Acceptance criteria: Theoretical plates ≥2000; Retention time ≥ 2; Asymmetry≥2. 
Result: 
Standard solution of Metformine HCl and Repaglinide was determined under 
proposed condition chromatogram indicating satisfactory % RSD of peak responses, 
theoretical plates, asymmetry and retention time. 
SPECIFICITY: 
Acceptance criteria: No interference at the Rt of Metformine HCl and Repaglinide. 
Result: From the specificity performed, various degradation products are formed and 
there is no change in the detection of the analyte in the presence of other components. 
 
 
 
LINEARITY: 
Linearity data for Repaglinide: 
 
Various concentrations of the Repaglinide was made by diluting stock solution to get 
the concentration of 0.1 to 0.6 μg. The dilution volumes used and peak area obtained 
are presented below 
Table 4: Linearity data for Repaglinide 
 
S. 
NO 
 
Concentration  
µg/ml    
Peak 
Area 
Statistical Analysis 
1. 0.1 24.459   
2. 0.2 49.334 Slope: 247.29 
3. 0.3 70.556   
4. 0.4 97.251 Intercept: 1.0552 
5. 0.5 123.888   
6. 0.6 147.491 Correlation coefficient: 0.999 
 
 
Calculation for ppm: 
Std wt x 1x 1000 
    100 x 100 
    1 x 1 x 1000          =     0.1 ppm 
      100 x 100 
   1 x 2 x 1000          =     0.2 ppm 
     100 x 100  
 
y = 247.29x - 1.0552 
R² = 0.999 
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Conc 
Linearity of Repaglinide 
 
1 x 3 x 1000          =     0.3 ppm 
100 x 100  
1 x 4 x 1000          =     0.4 ppm 
100 x 100  
1 x 5 x 1000          =     0.5 ppm 
100 x 100  
1 x 6 x 1000          =     0.6 ppm 
100 x 100  
Acceptance criteria: r
2 
should not be less than 0.99 
Result: The relationship between the concentration and the peak response of 
Repaglinide was linear in the specific range and the regression coefficient was found 
to be 0.999. 
Linearity data for Metformin HCl: 
Various concentrations of the metformin HCl was made by diluting stock solution to 
get the concentration of 25 to 150 μg. The dilution volumes used and peak area 
obtained are presented below 
Table 5: Linearity data for Metformin HCl 
S,. 
no 
Concentration  
µg/ml    
Peak 
Area 
Statistical Analysis 
1. 25 102.384   
2. 50 201.721 Slope: 3.9943 
3. 75 296.203   
4. 100 393.97 Intercept: 0.3973 
5. 125 505.63   
6.           150 599.49 Correlation coefficient: 0.9995 
 
  
Calculation for ppm: 
Std wt x 1x 1000 
 100 x 100 
250 x 1 x 1000          =     25 ppm 
100 x 100  
250 x 2 x 1000          =     50 ppm 
100 x 100  
250 x 3 x 1000          =     75 ppm 
100 x 100  
250 x 4 x 1000          =     100 ppm 
100 x 100  
250 x 5 x 1000          =     125 ppm 
100 x 100  
250 x 6 x 1000          =     150 ppm 
100 x 100  
y = 3.9943x + 0.3973 
R² = 0.9995 
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Conc 
Linearity of Metformin 
 
Acceptance criteria: r
2 
should not be less than 0.99 
Result:  The relationship between the concentration and the peak response of 
Repaglinide was linear in the specific range and the regression coefficient was found 
to be 0.9995. 
ACCURACY 
Accuracy studies for repaglinide: 
Accuracy for the Repaglinide was carried out at three different levels. The recovery 
data for repaglinide is shown in table below.  
1) Recovery data for repaglinide (0.45mcg): 
S.no Concentration(mcg) Area 
1 0.45 115.662 
2 0.45 114.275 
3 0.45 114.62 
 Average area 114.8523 
 
Calculation: 
Concentration of formulation =114.4013×0.5 
       128.694 
            = 0.446 mcg 
% Recovery                        =    0.446×100 
        0.45 
     = 99.16% 
2) Recovery data for repaglinide (0.55mcg): 
S.no Concentration(mcg) Area 
1 0.55 140.278 
2 0.55 140.101 
3 0.55 143.825 
 Average area 141.4013 
 
 
 
Calculation: 
Concentration of formulation =141.4013×0.5 
       128.6947 
            = 0.549 mcg 
Percentage of recovery           = 0.549×100 
          0.55 
     = 99.88% 
3) Recovery data for repaglinide (0.65mcg): 
S.no Concentration(mcg) Area 
1 0.65 169.913 
2 0.65 168.128 
3 0.65 167.945 
 Average area 167.945 
 
Calculation: 
Concentration of formulation =167.94×0.5 
      128.694 
             = 0.6524 mcg 
Percentage of recovery            = 0.6524×100 
          0.65 
      = 100.38% 
 
Table 6: Accuracy studies for repaglinide 
 
S.No 
Mixture of 
pure and 
formulation 
Con. of 
pure drug, 
µg/ml 
Conc. Of 
Formulation, 
µg/ml   
% Recovery of 
pure drug 
1. 0.4+0.05 0.05 0.446 99.16 
2. 0.5+0.05 0.05 0.549 99.88 
3. 0.6+0.05 0.05 0.652 100.38 
 
 
Accuracy studies for Metformin HCl: 
Accuracy for the Metformin HCl was carried out at three different levels. The 
recovery data for Metformin HCl is shown in table below. 
1) Recovery data for metformin (112.5mcg): 
S.no Concentration(mcg) Area 
1 112.5 468.646 
2 112.5 467.646 
3 112.5 464.123 
 Average area 466.805 
 
Calculation: 
Concentration of formulation     = area of sample × concentration of standard drug 
                 Average area of sample 
                                                      = 466.805×125 
       522.188 
                                                      =111.74 mcg. 
% Recovery                        =   Concentration of formulation×100 
 Concentration of sample 
     = 111.74×100  
 112.5 
      = 99.33% 
2) Recovery data for metformin (137.5mcg): 
S.NO Concentration(mcg) Area 
1 137.5 572.031 
2 137.5 574.675 
3 137.5 574.602 
 Average area 573.7693 
 
Calculation:  
Concentration of formulation = 573.769×125 
 522.188 
       =137.347 mcg 
 
Percentage of recovery           = 137.347×100 
 137.5 
        = 99.89% 
3) Recovery data for metformin (162.5mcg): 
S.NO Concentration(mcg) Area 
1 162.5 678.915 
2                                        162.5 678.376 
3 162.5 677.029 
 Average area 678.1067 
 
Calculation: 
Concentration of formulation =678.106×125 
 52.188 
            = 162.323 mcg 
Percentage of recovery           = 162.323×100 
 162.5 
     = 99.9% 
Table 7: Accuracy studies for Metformin HCl 
 
S.No 
Mixture of pure 
and formulation 
Con. of 
pure 
drug, 
µg/ml 
Conc. Of 
Formulation, 
µg/ml   
% Recovery of pure 
drug 
1. 100+12.5 12.5 111.74 99.33 
2. 125+12.5 12.5 137.35 99.89 
3. 150+12.5 12.5 162.32 99.89 
 
Report: The percentage recovery of Repaglinide ranges from 99.16- 100.38% and 
Metformin HCl ranges from 99.33- 99.89% which are  well within the acceptance 
criteria of 90-110% showing that there is no interference from excipients for the 
proposed method. 
 
ROBUSTNESS 
Table 8. Effect of flow rate 
           Flow rate    RT of Repaglinide RT of Metformin Hcl 
0.9 mL/ min 2.420         5.640 
1.1 mL/ min 4.903 1.907 
Table 9. Change in wavelength 
Wave length RT of Repaglinide RT of Metformin Hcl 
228 nm 5.437 2.057 
232 nm 5.337 2.050 
 
PRECISION 
Precision: 
The system precision is checked to ensure that the analytical system is working 
properly. The retention time and area of six determinations is measured and % RSD 
was calculated and represented below. 
Table 10: Precision data for Metformin HCL and Repaglinide 
 
S.no 
Metformin HCl Repaglinide 
Retention Area Retention Area 
1 2.113 510.122 6.007 126.374 
2 2.08 511.699 5.987 125.187 
3 2.077 517.179 5.99 127.642 
4 2.113 509.128 6.007 127.376 
5 2.08 519.359 5.98 126.796 
avg 2.0926 513.4974 5.9942 126.675 
stdev 0.018663 4.517515 0.012235 0.967713 
%RSD 0.89 0.88 0.20 0.76 
 
 
 
Calculation: 
  % RSD for Metformin     = Standard deviation ×100 
              Mean 
 
     = 0.018663×100 
 2.0926 
      = 0.891 
% RSD for Repaglinide      = 0.012235×100 
      5.9942 
 = 0.2041 
Amount of Metformin HCl present in mg: 
 
=       Avg sample area x Std wt x dilution factor xTablet wt taken x Std purity 
                                     Avg std area x Sample wt x 100          
 
=        513.4974 x 500 x 820 x 99.8           
                514.709 x 819 x 100 
=        498.433 mg 
 
Assay in % =   498.33 x 100 
                              500 
                    =   99.68 % 
 
 
 
 
 
 
 
Amount of Repaglinide present in mg: 
 
=   Avg sample area x Standard wt x dilution factor x Tablet wt taken x Std purity 
Avg std area x Sample wt x 100 
 
=        126.675 x 2 x 820 x 99.9          
             128.307 x 819 x 100 
=        1.97 mg 
 
Assay in % =   1.97 x 100 
                              2 
                    =   98.68 % 
Report: 
From the precision data of the system, the % RSD for Repaglinide and Metformin 
HCl were found to be 0.76 and 0.88 respectively. Hence, the precision of the system 
as found to be well within the acceptance criteria (not less than 2%).  
RUGGEDNESS 
The determination was performed by two different analyst (A-1 & A-2) and the 
chromatograms were recorded. The % RSD was calculated from the peak area. 
Table 11: Ruggedness for Repagl;inide and Metformin HCl 
 
 
      Analyst  
Retention time of 
Repaglinide(min) 
Retention time of 
Metformin Hcl(min) 
Analyst 1 5.583 2.193 
Analyst 2 5.583 2.193 
 
Report: 
From the ruggedness data, the % RSD of peak area by A-1 & A-2 for Repaglinide and 
Metformin HCl were found to be 5.588 & 2.193 respectively. 
METHOD PRECISION 
The method precision data for Repaglinide and Metformin HCl were presented in 
table below. 
Table 12: Method precision for Repaglinide and Metformin HCl 
 
S.no 
Metformin HCl Repaglinide 
Retention Area Retention Area 
1 2.077 516.525 5.973 127.447 
2 2.077 522.248 5.987 128.434 
3 2.077 521.713 5.987 127.754 
4 2.077 521.242 5.987 127.43 
5 2.077 522.998 5.987 126.176 
avg 2.077 520.9452 5.9842 127.4482 
stdev 0 2.555731 0.006261 0.819167 
%RSD 0.00 0.49 0.10 0.64 
 
Amount of Repaglinide present in mg: 
 
=   Avg sample area x Standard wt x dilution factor x Tablet wt taken x Std purity 
Avg std area x Sample wt x 100 
 
=        520.945 x 500 x 820 x 99.8          
             514.709 x 819 x 100 
 
=        505.66 mg 
 
Assay in % =   505.66 x 100 
                              500 
                    =   101.13 % 
 
Amount of Repaglinide present in mg: 
=   Avg sample area x Standard wt x dilution factor x Tablet wt taken x Std purity 
Avg std area x Sample wt x 100 
 
=        127.448 x 2 x 820 x 99.9          
             128.307 x 819 x 100 
 
=        1.98 mg 
 
Assay in % =   1.98 x 100 
                              2 
                    =   99.0 % 
 
Report: From the precision data of the method, the % RSD for Repaglinide and 
Metformin HCl were found to be 0.64 and 0.49 respectively. Hence, the precision of 
the method was found to be well within the acceptance criteria (not more than 2%). 
ASSAY 
The assay of the standard and samples were carried out with respect to assay 
procedure from reported method and the marketed samples was analysed to determine 
the content of Repaglinide and Metformin HCl. 
 
 
 
 
Table 13: Assay for Repaglinide and Metformin HCl 
Drug    injection Peak area Amount 
present 
% Assay 
  
Repaglinide  
1. 
127.754 
  
2. 
127.43 
1.99 99.46 
Metformin 
hydrochloride 
1. 
515.713 
499.87 99.97 
2. 
514.242 
  
 
Calculation for Metformin HCl: 
=       Avg sample area x Standard wt x Tablet wt taken x Standard purity 
Avg std area x Sample wt x 100 
 
= 514.9775 x 500 x 820 x 99.8        =            499.87 mg 
     514.709 x 819 x 100 
Assay %   = 499.87 x 100 
        500 
        =   99.97 % 
Calculation for Repaglinide: 
=       Avg sample area x Standard wt x Tablet wt taken x Standard purity 
Avg std area x Sample wt x 100 
=   127.59 x 2 x 820 x 99.9        =            1.99 mg 
     128. 3077 x 819 x 100 
 
Assay %   =   1.99 x 100 
        2 
        =   99.5 % 
SUMMARY AND CONCLUSION 
A very few analytical methods appeared in the literature for the determination 
of metformin hydrochloride and repaglinide are generally based HPLC, UV, Spectro 
fluorimetry. That has been reported for the quantification of metformin hydrochloride 
and repaglinide.  
In the present work, an attempt was made to provide a newer, simple accurate 
and low cost post column derivatization of spectrophotometric and there derivative 
method and one HPLC method for the effective quantitative determination of  
metformin HCL  and repaglinide as an active pharmaceutical ingredient as well as in 
pharmaceutical preparations without the interferences of other constituent  in the 
formulations. 
For routine analytical purposes it is always of interest to establish methods 
capable of analyzing a large number of samples in a short time period with good 
accuracy and precision. The main purpose of the study was to develop accurate, 
precise and economic methods for the determination of Metformin HCL and 
Repaglinide. Spectrophotometric technique, and post column derivatization method 
were applied without using any prior chemical pretreatment in the presence of the 
strongly overlapping spectra can generate large amounts of data within a short period 
of analysis. 
An HPLC method is developed and validated for various parameters as per 
ICH guidelines. The system suitability parameters prove that the proposed method is 
equally suitable for estimation of Metformine HCL and Repaglinide, the 
chromatogram for Metformin HCl and Repaglinide were found to be satisfactory on 
RP-18(2), 250X4.6mm, 5µm column, using mobile phase combination of buffer: 
acetonitrile (58:42 v/v) with flow rate of 1.0 ml/min. Both the peaks were found to be 
symmetrical as found from symmetry factor of 1.01 for Metformin HC l and 
Repaglinide. 
The resolution of the proposed method was found to be satisfactory, with peak 
showing complete baseline separation. The retention rime for Metformin HCl about 
5min, and Repaglinide was about 2min. The proposed system of satisfactory phase 
and mobile phase was ideally suitable for the estimation as indicated by good number 
of theoretical plates 5689 per meter for Metformin HCl and Repaglinide. 
The sensitivity of the method is good and also linearity which is observed is 
good. 
The accuracy of the method is determined by recovery with spiked 
concentration of pure drug at three levels for metformin HCl and Repaglinide. The 
recovery of drug is well within the acceptance limits of 97-103%. 
The method is rugged and robust as observed from insignificant variation in 
the results of analysis on changes in mobile phase composition ratio, pH, flow rate, 
temperature and analysis being performed by different analysts and on different days 
respectively. In the all above cases the recovery is found to be within the limit. 
 
  
 
 
 
CONCLUSION 
An HPLC method was developed and validated successfully for simultaneous 
estimation of Repaglinide and Metformin HCl in tablet dosage form. The present 
study was validated as per the ICH guidelines and the method was found to be 
accurate, precise, linear, specific and reproducible for the simultaneous determination 
of Repaglinide and Metformin HCl in formulation. 
From the comprehensive validation conducted, it was concluded that the 
method is stable and could be used throughout shelf life of the drug. 
Hence this study can be extended by studying the degradation kinetics of 
Repaglinide and Metformin HCl determination by RP-HPLC method and also its 
estimation in plasma and biological fluids. 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
1. Gary D. Christian Analytical chemistry 6th edn, John Willey and Sons Ltd., 
New Delhi, 2003, Prefix 5. 
2. Anonymous. http://www.pmd.com. 
3. Vogel’s, Text book of  Quantitative Chemical Analysis 6th edn, Pearson 
Education Pvt. Ltd., New Delhi, 2004,  1, 4. 
4. Brereton RG. Introduction to multivariate calibration in analytical chemistry. 
Analyst, 2000, 125(111), 2125-2154. 
5. Willard H. H., Metrit, L. L., Dean, J.A and Settle, F.A. Instrumental methods 
of Analysis. 7
th
 edn, CBS Publishers and Distributors, New Delhi, 1986, 11. 
6. Chatwal and Anand. Instrumental methods of Chemical Analysis.1st edn. 
Himalaya Publishing House, Mumbai, 2008, 1(2), 1.3. 
7. Sethi P. D. Quantitative analysis of pharmaceutical formulation 1st edn, 
Sathish kumar Jain for CBS publishers and distributors, New Delhi–110002, 
2001, 3-12. 
8. Wold S, Martens H, Wold H. The multivariate calibration problem in Chem 
solved by PLS method. Heidelberg: Springer; 1983. 
9. Michael E, Schartz I.S, Krull. Analytical method Development and validation. 
2004: 25-46. 
10. Code Q2A, Text on validation of analytical procedures, ICH Harmonized 
Tripartite guidelines, Geneva, Switzerland, 27October, 1994, 1-5. 
11. Berry RI and Nashar.  Pharmaceutical process validation, analytical method 
validation. Marcel Dekker inc new york, 1993; 57: 411-428. 
12. Beckett, A. H and J. B.Stenlake. Practical Pharmaceutical Chemistry. 4th 
edition, CBS Publishers and Distributors,Bre New Delhi, 2007, 16, 17. 
13. Stone M. Cross-validatory choice and assessment of statistical predictions. J. 
Roy. Stat. Soc., 1974; 36(2): 111-147. 
14. Anonymous www. Wiki. com 
15. Anonymous www.drug bank.ca 
16. Anonymous www.drug bank.ca 
17. Bhaskar Laxmanrao Kolte, Bharat Baburao Raut , Adwait Anant Deo, Manoj 
Anil Bagool and  Devanand Baburao Shinde. Simultaneous determination of 
metformin and glimepride in pharmaceutical dosage form by reverse-phase 
liquid chromatography, Journal of Separation Science, 2005; 28(16):  2076–
2079.  
18. Arayne MS, Sultana N, Zuberi MH. Development and validation of RP-HPLC 
method for the analysis of metformin. Pak J Pharm Sci 2006 Jul; 19(3):231-5. 
19. Sahoo PK, Sharma R, Chaturvedi SC. Simultaneous estimation of metformin 
hydrochloride and pioglitazone hydrochloride by RP-HPLC method from 
combined tablet dosage from. Indian J Pharm Sci 2009; 70:383-6. 
20. Sadaf Saeed. Simultaneous estimation of Pioglitazone and metformin HCl in 
tablet dosage form along with in vitro studies. Journal of Pharmacy Research, 
2009, 2(9), 15-23. 
21. Mousumi Kar and Choudhury PK. HPLC Method for Estimation of 
Metformin Hydrochloride in Formulated Microspheres and Tablet Dosage 
Form. Indian J Pharm Sci. 2009 ; 71(3): 318–320 
22. Lakshmi KS, Rajesh T, Shrinivas S.  Determination of pioglitazone and 
glimepiride in pharmaceutical formulation and rat plasma by RP-LC. Int J 
Pharm Tech Res 2009; 1:496-9. 
23. Onal A. Spectrophotometric and HPLC determinations of anti-diabetic drugs, 
Rosiglitazone maleate and Metformin hydrochloride, in pure form and in 
pharmaceutical preparations.  Eur J Med Chem 2009, ; 44(12):4998-5005.  
Pharmaceuctial drug products. International journal of research and reviews in 
pharmacy and applied sciences, 2011; 1(3): 131-139.  
24. Narsimha rao. Doredla, Shanmugasundaram  P and Hemant vaishnav. Method 
Development and Validated of Simultaneous Estimation of Metformin 
Hydrochloride, Pioglitazone Hydrochloride and Glibenclamide in Pure and 
Tablet dosage form by Spectrophotometric Multi component Method. Int.J. 
ChemTech Res.2011, 3(4). 
25. Serasiya TH, Gabhe SY and Jivani NP. Simultaneous Determination of 
Enalapril Maleate and Metformin Hydrochloride in Pharmaceutical 
Composition by RP- HPLC Method, International Journal of Chemical and 
Analytical Science, 2011; 2: 10. 
26. Angshuman Biswas and Arindan Basu. A novel RPHPLC method for 
simultaneous estimation of metformin HCl and glimepride in tablet dosage 
form, IJPI’s journal of analytical chemistry, 2011, 2(7),11-15. 
27. Bhaskar Reddy L, Raveendra Reddy P, Useni Reddy Mallu and Maheshwara 
Reddy L. Novel rp-hplc method for Metformin Hcl, Glipizide and Repaglinide 
pharmaceutical drug products, International journal of research and reviews in 
pharmacy and applied sciences, 2011, 1(3), 131-139. 
28. Bhamare PC, Bari SB, Natrajan S, Patil AA, Patil SH and Shirode PT. 
Development and Validation of a precise single stability indicating HPLC 
method for determinations of Metformin hydrochloride and Fenofibrate, in 
pure form and in Pharmaceutical tablets. Int.J. PharmTech Res, 2011; 3(1): 
505. 
29.  Venkatesh P., Harisudhan T., Hira Choudhury., Ramesh Mullangi and 
Srinivas R. Simultaneous estimation of six antidiabetic drugs-glimepramide, 
gliclazide, glipizide, pioglitazone, repaglinide, metformin and rosiglitazone: 
development of a novel HPLC method for use in the analysis of 
pharmaceutical formulation and its application to human plasma assay, 
Biomedical Chromatography, 2006, 20(10), 1043-1048. 
30. Kaushal N, Jain S, Tiwary A.K. Development of spectrofluorimetric and 
HPLC methods for in vitro analysis of Repaglinide, Indian Journal of 
pharmaceutical Sciences, 2010, 72(2), 240-244. 
31.  Love Kumar Soni, Tamana Narasinghani and Madhavi Jain. Development 
and validation of RP-HPLC method for simultaneous estimation of metformin 
HCl, Repaglinide in tablet dosage form, Journal of liquid chromatography and 
related technology, 2012, 35(3), 385-364. 
32.  Deepa R.Patel, Laxman Bhai J. Patel and Madha Bhai M. Patel. Stablity 
indicating HPLC method for simultaneous determination of Repaglinide and 
Metformin HCl in pharmaceutical dosage form, Asian Journal of Research in 
Chemistry, 2011, 4(3), 500-505. 
33. Anonymous. Instruction Manual Shimadzu AX-200 Digital balance, 
Shimadzu Corporation, Kyoto, Japan, 2001, 42. 
34. Anonymous. Instruction manual. Shimadzu spd-10 Avp UV-VIS detector 
Shimadzu Corporation, Kyoto, Japan, 2001, 11.2. 
35. Anonymous. Shimadzu Instruction Manual Pharmaspec UV-1700 series 
operation guide, Shimadzu Corporation, Kyoto, Japan, 2001, 6-2. 
36. Anonymous. http://pubs.acs.org. 
37. Anonymous. http://www.springerlink.com. 
38. Sharma B. K. Organic Spectroscopy, Goel Publishing House, Krishna 
Prakashan media, Meerut(U.P), 2002, S-75. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
